Inquirer News

Senate bill seeks to institutionalize FDA’s authority to issue EUAs

UNAUTHORIZED FDA DISCRETION: Sen. Francisco “Tol” Tolentino, in his privilege speech during the hybrid plenary session Tuesday, January 19, 2021, questions the authority of the Food and Drug Administration (FDA) to issue circulars which, he said, could not be found in any provisions of Republic Act No. 9711 that created FDA. “I'm not demeaning the FDA, they're trying to do their best. But I think they are utilizing their functions in an inappropriate manner,” Tolentino said. The senator said the Emergency Use Authorization (EUA) cropped up following the issuance of Executive Order 121 authorizing FDA to issue such authorization. However, he said, the EO does not limit the procurement of COVID-19 vaccines to the national government. He earlier stressed that the FDA law could not be amended by an EO. “So what is happening now, Mr. President, is that the FDA issued circulars left and right and thereafter belatedly amended its circulars to include that words 'emergency use authorization' and thereafter interpreted their own circulars, which they would implement... it appears that the FDA is the legislator, the FDA is the executive, and the FDA is the judge as the sole interpreter of the circulars that they issued. This is really a classic case of undue delegation of legislative powers,” Tolentino said. (Joseph Vidal/Senate PRIB)

MANILA, Philippines — Senator Francis Tolentino has filed a bill seeking to institutionalize the authority of the Food and Drug Administration (FDA) to issue an emergency use authorization (EUA).

In filing Senate Bill No. 2024, Tolentino noted that existing laws “do not provide for or contemplate” the grant of EUA by the FDA.

While President Rodrigo Duterte earlier issued an executive order allowing the FDA to issue EUAs for Covid-19 drugs and vaccines, the senator said “it could be argued that this is insufficient to clothe the said agency with the authority to do so.”

Executive orders, Tolentino noted “cannot amend, revise, repeal, or in any way, alter what is stated under a law passed by Congress.”

In order to address the “glaring void” in the law that would deem the FDA’s EUA issuances “subject to stricter legal scrutiny,” the bill seeks to amend the Republic Act No. 3720 or the Food, Drug and Cosmetic Act to define EUA and provide the parameters for its issuance.

“The proposed measure not only gives legitimacy to the circulars issued by the FDA on EUA but also ensures the faster and smoother procurement and distribution of vaccines to the Filipino people during a public health emergency,” Tolentino said.

Under the measure, an EUA is defined as an authority issued by the FDA chief allowing the use of unapproved health products during a public health emergency or threat or when there is no “adequate” or approved product to treat “serious or life-threatening diseases or conditions.”

“The emergency use may either be for an unapproved health product or for an unapproved use of an approved health product,” the bill said.

The measure also mandates the FDA, in consultation with the Department of Health, Department of Science and Technology and other relevant agencies to issue “emergency use instructions” to “inform health care providers and individuals, to whom an eligible product under this Act is to be administered, concerning such product’s EUA.”

EDV
Exit mobile version